Market Place
Sourcing Support
Emalex eyes potential Tourette approval after phase 3 win
26 Feb 2025 //
FIERCE BIOTECH
Emalex Releases Results of 12-Month Open-Label Extension Study
05 Oct 2023 //
BUSINESSWIRE
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam
01 Mar 2023 //
PR NEWSWIRE
Emalex Biosciences reports data from Tourette syndrome therapy trial
12 Jan 2023 //
CLINICAL TRIALS ARENA
Emalex Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics
11 Jan 2023 //
PR NEWSWIRE
Tourette-focused Emalex rakes in $250M series D
03 Nov 2022 //
FIERCEBIOTECH
Emalex Bio Expands CNS Platform to Advance Treatment for Restless Legs Syndrome
01 Mar 2022 //
PRNEWSWIRE
Emalex Biosciences initiates PII Trial for Childhood-Onset Fluency Disorder
14 Sep 2021 //
PRNEWSWIRE
Jeff Aronin`s Emalex raises $35M Series C; British protein degradation
23 Mar 2021 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.